Literature DB >> 33673443

Synthesis of Chromeno[3,4-b]piperazines by an Enol-Ugi/Reduction/Cyclization Sequence.

Ana Bornadiego1, Ana G Neo1, Carlos F Marcos1.   

Abstract

Keto piperazines and aminocoumarins are privileged building blocks for the construction of geometrically constrained peptides and therefore valuable structures in drug discovery. Combining these two heterocycles provides unique rigid polycyclic peptidomimetics with drug-like properties including many points of diversity that could be modulated to interact with different biological receptors. This work describes an efficient multicomponent approach to condensed chromenopiperazines based on the novel enol-Ugi reaction. Importantly, this strategy involves the first reported post-condensation transformation of an enol-Ugi adduct.

Entities:  

Keywords:  Ugi reaction; chromones; coumarins; enols; heterocycles; isocyanides; multicomponent reactions; peptidomimetics; piperazines; pyrazines

Mesh:

Substances:

Year:  2021        PMID: 33673443      PMCID: PMC7956738          DOI: 10.3390/molecules26051287

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  32 in total

Review 1.  Praziquantel and schistosomiasis.

Authors:  Alexander Dömling; Kareem Khoury
Journal:  ChemMedChem       Date:  2010-09-03       Impact factor: 3.466

2.  Bicyclic Piperazine Mimetics of the Peptide β-Turn Assembled via the Castagnoli-Cushman Reaction.

Authors:  Liliia Usmanova; Dmitry Dar'in; Mikhail S Novikov; Maxim Gureev; Mikhail Krasavin
Journal:  J Org Chem       Date:  2018-05-03       Impact factor: 4.354

Review 3.  Coumarin heterocyclic derivatives: chemical synthesis and biological activity.

Authors:  Fernanda G Medina; Joaquín G Marrero; Mariana Macías-Alonso; Magdalena C González; Iván Córdova-Guerrero; Ariana G Teissier García; Soraya Osegueda-Robles
Journal:  Nat Prod Rep       Date:  2015-09-23       Impact factor: 13.423

4.  Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.

Authors:  Mirna Jovanović; Daniil Zhukovsky; Ana Podolski-Renić; Ilona Domračeva; Raivis Žalubovskis; Milan Senćanski; Sanja Glišić; Vladimir Sharoyko; Tatiana Tennikova; Dmitry Dar'in; Milica Pešić; Mikhail Krasavin
Journal:  Eur J Med Chem       Date:  2019-08-01       Impact factor: 6.514

5.  Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors.

Authors:  Jinbo Zhao; Huiping Zhao; Jessica A Hall; Douglas Brown; Eileen Brandes; Joseph Bazzill; Patrick T Grogan; Chitra Subramanian; George Vielhauer; Mark S Cohen; Brian S J Blagg
Journal:  Medchemcomm       Date:  2014-09-01       Impact factor: 3.597

6.  Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.

Authors:  Atmaram D Khanolkar; Dai Lu; Mohab Ibrahim; Richard I Duclos; Ganesh A Thakur; T Phillip Malan; Frank Porreca; Vijayabaskar Veerappan; Xiaoyu Tian; Clifford George; Damon A Parrish; Demetris P Papahatjis; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2007-11-27       Impact factor: 7.446

Review 7.  The promiscuous estrogen receptor: Evolution of physiological estrogens and response to phytochemicals and endocrine disruptors.

Authors:  Michael E Baker; Richard Lathe
Journal:  J Steroid Biochem Mol Biol       Date:  2018-07-20       Impact factor: 4.292

8.  Enols as feasible acid components in the Ugi condensation.

Authors:  Teresa G Castellano; Ana G Neo; Stefano Marcaccini; Carlos F Marcos
Journal:  Org Lett       Date:  2012-11-30       Impact factor: 6.005

Review 9.  Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid.

Authors:  Claudia Ceci; Pedro M Lacal; Lucio Tentori; Maria Gabriella De Martino; Roberto Miano; Grazia Graziani
Journal:  Nutrients       Date:  2018-11-14       Impact factor: 5.717

Review 10.  Coumarin-piperazine derivatives as biologically active compounds.

Authors:  Kinga Ostrowska
Journal:  Saudi Pharm J       Date:  2019-12-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.